Neoadjuvant therapy for breast cancer: Evolution of practical guidelines
O. V. Korshunova,
V. I. Apanasevich,
E. V. Eliseeva,
O. A. Argishev,
K. V. Stegniy,
Yu. Yu. Petukhova,
O. M. Zagrudinova https://doi.org/10.34215/1609-1175-2025-4-11-15
Abstract
The article provides an analytical review of neoadjuvant therapy for breast cancer, observing a paradigm shift in treatment over the past decade. This shift is due to emerging knowledge about the nature of the disease and opportunities to achieve better treatment outcomes. During the period under review, neoadjuvant therapy for breast cancer has evolved from standard regimens to dose-dense regimens, and to dual blockade (trastuzumab/pertuzumab) in the treatment of HER2-positive tumors.
About the Authors
O. V. Korshunova
Pacific State Medical University
Russian Federation
Russian Federation
Oksana V. Korshunova, Cand. Sci. (Med.), Associate Professor of the Department of General and Clinical Pharmacology
2 Ostryakova Ave., Vladivostok, 690002, Russia
tel.: +7 (908) 448-91-13
V. I. Apanasevich
Pacific State Medical University;
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
Vladivostok
E. V. Eliseeva
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
O. A. Argishev
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
Vladivostok
K. V. Stegniy
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
Vladivostok
Yu. Yu. Petukhova
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
Vladivostok
O. M. Zagrudinova
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
Vladivostok
References
1. Komissarova VA, Safontsev IP, Zukov RA. Clinical and morphological parameters and assessment of disease prognosis in patients with breast cancer under 40 years of age. Malignant Tumours. 2025;15(1):17–26 (In Russ.). doi: 10.18027/2224-5057-2025-038
2. Podregulskiy KE, Poddubnaya IV. Organizational and methodological aspects of the implementation of a Regional treatment program for locally advanced and metastatic breast cancer using the docetaxel/doxorubicin regimen. Journal of Modern Oncology. 2003;5(1):6–7 (In Russ.).
3. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85. doi: 10.1158/1078-0432.CCR-04-2421
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34. doi: 10.1158/1078-0432.CCR-06-1109
5. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84. doi: 10.1093/annonc/mdt182
6. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323
7. Petrenko OL. The peculiarities of surgical service of locally advanced breast cancer after neoadjuvant systemic treatment. The Scientific Notes of the Pavlov University. 2015;22(3):42–47 (In Russ.).
8. Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Effect of adjuvant paclitaxel and carboplatin on survival in women with triplenegative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390–96. doi: 10.1001/jamaoncol.2020.2965
9. Tjulandin SA, Artamonova EV, Zhigulev AN, Zhukova LG, Koroleva IA, Parokonnaya AA, Semiglazova TYu, Stenina MB, Frolova MA Practical recommendations for drug treatment of breast cancer. Malignant Tumors. 2023;13(3s2–1):157–200 (In Russ.). doi: 10.18027/2224-5057-2023-13-3s2-1-157-200
10. Tjulandin SA, Artamonova EV, Zhigulev AN, Zhukova LG, Koroleva IA, Parokonnaya AA, Semiglazova TYu, Stenina MB, Frolova MA Breast cancer. Malignant Tumors. 2024;14(3s2–2):32–81 (In Russ.). doi: 10.18027/2224-5057-2024-14-3s2-1.2-01
11. Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, Khan QJ, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, del Monte-Millán M, González-Rivera M, Massarrah T, PelaezLorenzo B, Palomero MI, González del Val R, Cortés J, FuentesRivera H, Morales DB, Márquez-Rodas JL, Amin AL, O’Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24(23):5820–29. doi: 10.1158/1078-0432.ccr-18-0585
12. Ganshina IP, Ivanova KA, Lubennikova EV, Arkhipov AV, Zhukova LG. Improving early breast cancer treatment: The role of granulocyte colony-stimulating factor. Journal of Modern Oncology. 2020;22(4):86–90 (In Russ.). doi: 10.26442/18151434.2020.4.200510
13. Frolova MA, Glazkova EV, Petrovsky AV, Krokhina OV, Stenina MB, Tjulandin SA. The role of the neoadjuvant approach in the treatment of primary operable HER2-positive breast cancer. Malignant Tumors. 2020;10(2):45–52 (In Russ.). doi: 10.18027/2224-5057-2020-10-2-4
14. Deshkina TI, Bolotina LV, Kornietskaya AL, Golubev PV, Gabunia IE, Ruban MS, Fedenko AA, Kaprin AD De-escalation of neoadjuvant therapy as an option for patients with HER2 positive breast cancer. Malignant Tumors. 2023;13(3):29–36 (In Russ.). doi: 10.18027/2224-5057-2023-13-3-29-36
15. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: Three-year outcomes from the phase III KRISTINE study. Clin. Oncol. 2019;37(25):2206–16. doi: 10.1200/JCO.19.00882
16. Untch M, Loibl S, Mano MS, Huang C‐S, Mamounas EP, Wolmark N, Knott A, Siddiqui A, Boulet T, Nyawira B, Restuccia E, Geyer CE. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. Oncol Res Treat. 2024;47(Suppl. 1):233–234. doi: 10.1159/000535363
17. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. doi: 10.1056/NEJMoa1814017
18. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. doi: 10.1056/NEJMoa1209124
Review
For citations:
Korshunova O.V., Apanasevich V.I., Eliseeva E.V., Argishev O.A., Stegniy K.V., Petukhova Yu.Yu., Zagrudinova O.M. Neoadjuvant therapy for breast cancer: Evolution of practical guidelines. Pacific Medical Journal. 2025;(4):11-15. (In Russ.) https://doi.org/10.34215/1609-1175-2025-4-11-15
Views:
235
JATS XML
Email this article 